# US 2024/0390400 A1 · Enpp1 inhibitors as inhibitors of metastasis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0390400 A1
- Document ID: US20240390400A1
- Status: Published application
- Kind: A1
- Application number: 18/647,254
- Filed: 2024-04-26
- Published: 2024-11-28
- Earliest claimed: 2021-10-29
- Assignees: Angarus Therapeutics, Inc.
- Applicants: Angarus Therapeutics, Inc.
- Inventors: Jackie Papkoff; Randolph Mellus Johnson; Neil A. Verity; Nigel Ray; James Johnston
- Web page: https://patentgrep.com/patent/US20240390400A1

## CPC

- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61P 35/00: Antineoplastic agents
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/662: Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/04: specific for metastasis
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Methods are provided for the treatment or prevention of metastasis by the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with a cell impermeable ENPP1 inhibitor to treat or prevent metastasis. Aspects of the methods include administering to a subject in need thereof a therapeutically effective amount of an immune checkpoint inhibitor, a chemotherapeutic agent, and/or radiation treatment, in combination with a therapeutically effective amount of a cell impermeable ENPP1 inhibitor to treat or prevent metastasis.

## Claims

### Claim 1

A method of treating, reducing, or preventing metastasis of cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition comprising an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, further comprising administering to the subject a therapeutically effective amount of a composition comprising an immune checkpoint inhibitor in combination with the composition comprising an ENPP1 inhibitor.

### Claim 3 (depends on 1)

The method of claim 1, further comprising administering to the subject a therapeutically effective amount of a composition comprising a chemotherapeutic agent in combination with the composition comprising an ENPP1 inhibitor.

### Claim 4 (depends on 1)

The method of claim 1, further comprising administering radiation therapy to the subject.

### Claim 5 (depends on 1)

The method of claim 1, wherein the ENPP1 inhibitor comprises the formula (VI):
wherein,
X is a hydrophilic head group selected from boronic acid, hydroxamic acid, phosphonic acid, phosphonate, phosphonate ester, phosphate, phosphate ester, thiophosphate, thiophosphate ester, phosphoramidate and thiophosphoramidate;
L is a linker;
Z1 and Z2 are each independently selected from CR1 and N;
Z3 and Z4 are each independently selected from CR and N, wherein R is H, alkyl or substituted alkyl;
each R1 is independently selected from H, cyano, trifluoromethyl, halogen, amino, alkyl, substituted alkyl, alkenyl, substituted alkenyl, heterocycle and substituted heterocycle;
R2 and R5 are each independently selected from H, OH, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substituted alkoxy, —OCF3, halogen, amine, substituted amine, amide, heterocycle and substituted heterocycle;
R3 and R4 are each independently selected from H, OH, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substituted alkoxy, —OCF3, halogen, amine, substituted amine, amide, heterocycle and substituted heterocycle; or R3 and R4 together with the carbon atoms to which they are attached form a fused ring selected from heterocycle, substituted heterocycle, cycloalkyl, substituted cycloalkyl, aryl and substituted aryl;
or a pharmaceutically acceptable salt or a solvate thereof.

### Claim 6 (depends on 5)

The method of claim 5, wherein:
L is selected from —CH2—, —(CH2)2—, —(CH2)3—, —(CH2)4—, —(CH2)5— and —(CH2)6—;
X is selected from:
wherein:
Ra and Rb are each independently selected from aryl, alkyl, —CH2OC(O)Re, and —CH2OC(O)ORe; and
wherein Re is alkyl.

### Claim 7 (depends on 6)

The method of claim 6, wherein the ENPP1 inhibitor is of the formula:
wherein,
Z1 and Z2 are each N;
Z3 is N; and
Z4 is CH or N.

### Claim 8 (depends on 5)

The method of claim 5, wherein the portion of the ENPP1 inhibitor represented by
is selected from:

### Claim 9 (depends on 5)

The method of claim 5, wherein the ENPP1 inhibitor is selected from the group consisting of

### Claim 10

(canceled)

### Claim 11 (depends on 2)

The method of claim 2, wherein the immune checkpoint inhibitor is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, a programmed death 1 (PD-1) inhibitor, or a PD-L1 inhibitor.

### Claim 12 (depends on 11)

The method of claim 11, wherein the immune checkpoint inhibitor is atezolizumab, avelumab, durvalumab, cemiplimab, ipilimumab, pembrolizumab, or nivolumab.

### Claim 13

(canceled)

### Claim 14 (depends on 3)

The method of claim 3, wherein the chemotherapeutic agent is a cytotoxic agent.

### Claim 15 (depends on 3)

The method of claim 3, wherein the chemotherapeutic agent is selected from the group consisting of daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, and valrubicin.

### Claim 16 (depends on 15)

The method of claim 15, wherein the chemotherapeutic agent is doxorubicin.

### Claim 17 (depends on 1)

The method of claim 1, wherein the subject is to undergo or has undergone resection of a malignant tumor.

### Claim 18 (depends on 1)

The method of claim 1, wherein the method comprises suppressing or preventing the recurrence of the cancer.

### Claim 19 (depends on 1)

The method of claim 1, wherein the method comprises suppressing or preventing malignant tumor cells from colonizing or invading vascular tissue.

### Claim 20 (depends on 1)

The method of claim 1, further comprising administering to the subject radiation therapy and a therapeutically effective amount of a composition comprising an immune checkpoint inhibitor in combination with the composition comprising an ENPP1 inhibitor.

### Claim 21 (depends on 20)

The method of claim 20, wherein the immune checkpoint inhibitor is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, a programmed death 1 (PD-1) inhibitor, or a PD-L1 inhibitor.

### Claim 22 (depends on 20)

The method of claim 20, wherein the immune checkpoint inhibitor is atezolizumab, avelumab, durvalumab, cemiplimab, ipilimumab, pembrolizumab, or nivolumab.
